Valproic acid and the liver.
Valproic acid (VPA) is widely used as an anticonvulsant, but therapy with the drug has been associated with hepatotoxicity, either reversible hepatic dysfunction or irreversible hepatic failure. Both clinical and experimental studies have revealed several VPA-related biochemical abnormalities in the liver: inhibition of the beta-oxidation and synthesis of fatty acids and inhibition of gluconeogenesis, urea synthesis, oxidative phosphorylation, and the glycine cleavage system. Other abnormalities noted include alteration in the protein conformation of the internal mitochondrial membrane, hyperammonemia, and increased bile flow. The mechanisms of such hepatotoxicity, whether mediated by VPA or by its metabolites, are still little understood. Susceptibility to VPA hepatotoxicity may be enhanced by such conditions as starvation, inborn errors of metabolism, additional neurological disease, and concomitant administration of enzyme-inducing drugs.
D000596:Amino Acids / Q000378:metabolism; D002331:Carnitine / Q000378:metabolism; D056486:Chemical and Drug Induced Liver Injury; D004347:Drug Interactions; D005227:Fatty Acids / Q000378:metabolism; D006801:Humans; D008107:Liver Diseases / Q000378:metabolism; D014508:Urea / Q000096:biosynthesis; D014635:Valproic Acid / Q000009:adverse effects* / Q000493:pharmacokinetics
D000596:Amino Acids; D005227:Fatty Acids; D014635:Valproic Acid; D014508:Urea; D002331:Carnitine